For instance, African populations exhibit a higher proportion of poor prognostic tumours, with TNBC and HER2 expression rates exceeding 20%, while hormone-positive BC rates are closer to 50%, compared to over 70% in high-income settings [8,48]. This evidence concerns the gene ERBB2 and breast cancer.